Immunochemical quantification of crossline as a fluorescent advanced glycation endproduct in erythrocyte membrane proteins from diabetic patients with or without retinopathy
✍ Scribed by Yamaguchi, M.; Nakamura, N.; Nakano, K.; Kitagawa, Y.; Shigeta, H.; Hasegawa, G.; Ienaga, K.; Nakamura, K.; Nakazawa, Y.; Fukui, I.; Obayashi, H.; Kondo, M.
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 94 KB
- Volume
- 15
- Category
- Article
- ISSN
- 0742-3071
No coin nor oath required. For personal study only.
✦ Synopsis
Crossline is a novel advanced glycation endproduct (AGE) which has both a crosslink and fluorescence similar to AGE-protein in vivo. To assess the association of AGEs to the development of diabetic retinopathy we developed a sensitive and specific enzyme-linked immunosorbent assay (ELISA) for crossline in blood samples and investigated the association of the development of retinopathy and erythrocyte membrane protein (EMP)-crossline concentrations in patients with Type 2 diabetes mellitus (Type 2 DM). Crossline formation in EMP exceeded that in haemoglobin and was detectable in normal EMP samples without pretreatment by this ELISA system. Mean (±SE) EMP crossline levels were elevated 1.6fold in diabetic patients without retinopathy (7.6 ± 0.5 pmol mg -1 , p Ͻ 0.005), 2.2-fold in diabetic patients with non-proliferative retinopathy (10.5 ± 0.6 pmol mg -1 , p Ͻ 0.001) and 2.6-fold in diabetic patients with proliferative retinopathy (12.0 ± 0.6 pmol mg -1 , p Ͻ 0.001) compared with healthy control subjects (4.7 ± 0.5 pmol mg -1 ). Type 2 DM patients with retinopathy had significantly higher EMP-crossline levels than those without retinopathy (p Ͻ 0.005). Our data suggest that elevated EMP-crossline concentrations are associated with the presence of retinopathy in patients with Type 2 DM and EMP-crossline measured by our ELISA may provide a useful marker for assessing the role of glycation in the development of diabetic retinopathy.